William J. Gradishar, MD, Northwestern University

Articles by William J. Gradishar, MD, Northwestern University

Therapeutic Advances in Prophylaxis Against CIN

ByHope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center,William J. Gradishar, MD, Northwestern University,Rita Nanda, MD, The University of Chicago Medicine,Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center

December 3rd 2021

An overview of therapies used as prophylaxis against chemotherapy-induced neutropenia and projections on improving quality of life for patients with solid tumors with therapeutic advances.

CIN: Adopting SIMBA Therapy Into Clinical Practice

December 3rd 2021

A panel of oncologists react to their interest in using plinabulin as prophylaxis against chemotherapy-induced neutropenia in future clinical practice.

CIN: Takeaways From the PROTECTIVE-1 Study

ByHope S. Rugo, MD,Rita Nanda, MD, The University of Chicago Medicine,Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center,William J. Gradishar, MD, Northwestern University

November 12th 2021

An overview of the design and results of the PROTECTIVE-1 study of plinabulin versus pegfilgrastim in patients with solid tumors receiving docetaxel myelosuppressive chemotherapy.

Potential Dosing Strategies to Mitigate CIN

ByHope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center,William J. Gradishar, MD, Northwestern University,Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center

November 12th 2021

Considerations regarding the potential to prevent chemotherapy-induced neutropenia with newer therapeutic strategies as well as changes to treatment dosages.

CIN Prophylaxis and Bone Pain

ByHope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center,William J. Gradishar, MD, Northwestern University,Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center,Rita Nanda, MD, The University of Chicago Medicine

November 12th 2021

Recommendations regarding how to best manage patients who experience bone pain from chemotherapy-induced neutropenia prophylaxis with growth factor support.

Managing CIN in Patients With Breast Cancer

ByHope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center,Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center,Rita Nanda, MD, The University of Chicago Medicine,William J. Gradishar, MD, Northwestern University

November 5th 2021

Preventive therapies and factors that impact how to best mitigate chemotherapy-induced neutropenia in patients with breast cancer.

Managing Chemotherapy-Induced Neutropenia With G-CSFs

ByHope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center,Rita Nanda, MD, The University of Chicago Medicine,William J. Gradishar, MD, Northwestern University

October 29th 2021

Recommendations for intervening with growth factor support and important considerations for reducing or discontinuing anti-cancer therapy when patients show signs of neutropenia.

CIN Prophylaxis: Treating With G-CSFs

ByHope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center,William J. Gradishar, MD, Northwestern University,Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center

October 29th 2021

Advantages, in terms of safety and efficacy, of granulocyte colony-stimulating factors used as prophylaxis against chemotherapy-induced neutropenia.

G-CSFs for Chemotherapy-Induced Neutropenia

October 22nd 2021

Breast oncologists react to the availability of granulocyte colony-stimulating factors, used as prophylaxis against chemotherapy-induced neutropenia.

Consequences of Chemotherapy-Induced Neutropenia

ByHope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center,Rita Nanda, MD, The University of Chicago Medicine,William J. Gradishar, MD, Northwestern University,Tiffany Traina, MD, Memorial Sloan Kettering Cancer Center

October 22nd 2021

A panel of breast oncologists define chemotherapy-induced neutropenia in terms of how they assess risk and attempt to prevent treatment-related toxicities in patients with cancer.